➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Filanesib

Email this page to a colleague

« Back to Dashboard

What is the drug development status for Filanesib?

Filanesib is an investigational drug.

There have been 4 clinical trials for Filanesib. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2014.

The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and [disabled in preview]. The leading clinical trial sponsors are Array BioPharma, PETHEMA Foundation, and Celgene Corporation.

There are one hundred and thirty-eight US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Filanesib
Pembrolizumab (MK-3475) in MM Patients With Residual DiseaseAdknoma Health ResearchPhase 2
Pembrolizumab (MK-3475) in MM Patients With Residual DiseaseMerck Sharp & Dohme Corp.Phase 2
Pembrolizumab (MK-3475) in MM Patients With Residual DiseasePETHEMA FoundationPhase 2

See all Filanesib clinical trials

Clinical Trial Summary for Filanesib

Top disease conditions for Filanesib
Top clinical trial sponsors for Filanesib

See all Filanesib clinical trials

US Patents for Filanesib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Filanesib   Get Started Free Remote loading of sparingly water-soluble drugs into lipid vesicles ZONEONE PHARMA, INC. (San Francisco, CA)   Get Started Free
Filanesib   Get Started Free Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE)   Get Started Free
Filanesib   Get Started Free Peptidomimetic macrocycles as modulators of MCL-1 AILERON THERAPEUTICS, INC. (Cambridge, MA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.